ClinicalTrials.gg
Status unknownNCT03811080Updated Jun 25, 2019

Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non Erosive Reflux Disease

A Phase 3 interventional study of DWP14012 A mg and DWP14012 B mg in Non-Erosive Gastroesophageal Reflux Disease, sponsored by Daewoong Pharmaceutical Co. LTD.. Status unknown at 1 site in Korea, Republic of. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-06-25.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2019), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
327
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of — 8 open to participants now, 10 under way, none of them phase 3. Gastroesophageal Reflux · Korea, Republic of.

Planned enrollment
6th of 52
327 · median 54
Started
2019
with 2 others
Phase 3
11 of 71
none open now
Registered
36th of 71
by date
Lead sponsor
5 of 71
Daewoong Pharmaceutical Co. LTD.

Among the 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of, this one is the 6th largest by planned enrollment of the 52 interventional ones that give a count, is one of 3 that started in 2019, is one of 11 in phase 3, and was the 36th registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

8 of the 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Gastroesophageal Reflux with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate the superiority of efficacy of DWP14012, once daily (QD), compared to placebo in patients with non-erosive reflux disease at Week 4.

Read the detailed description

This is a multi-center, double blind, randomized, placebo-controlled, parallel-group, phase 3 study. Subjects will be randomly assigned to one of the three treatment groups (DWP14012 A mg or DWP14012 B mg or placebo).

03

Conditions studied

  • Non-Erosive Gastroesophageal Reflux Disease
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects aged between 20 and 75 years
  2. Subjects who were not observed mucosal break according to the LA classification(LA grade) on the EGD
  3. Subjects who had experienced major symptom within 3 months
  4. Subjects who had experienced major symptom within 7 days before randomization. Entry into study also required that patients had experienced at least mild symptoms on at least 2 days/week or at least moderate symptoms on at least 1 day/week
  5. Subjects who is able to understand and follow the instructions
  6. Subjects who voluntarily signed written form

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have Barrett's esophagus, gastroesophageal varices, esophageal stenosis, ulcer stenosis, active gastric ulcer, gastrointestinal bleeding or malignant tumor confirmed by endoscopy
  2. Subjects who have erosive esophagitis, acute upper gastrointestinal bleeding, gastric ulcers or duodenal ulcers within 2 months before Visit 1
  3. Subjects diagnosed with functional dyspepsia, primary esophageal motility disorder, IBS, IBD in the last 3 months
  4. Subjects who have a history of gastric acid suppression surgery or gastroesophageal surgery
  5. Subjects with Zollinger-Ellison syndrome
  6. Subjects with eosinophilic esophagitis
  7. Subjects with liver, kidney, nervous system, respiratory, endocrine, hematologic, cardiovascular, urinary system disease .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
327 participants (estimated)

Study arms

  • Experimental
    DWP14012 A mg

    DWP14012 A mg, tablet, once daily, oral administration for up to 4 weeks

    Drug: DWP14012 A mg

  • Experimental
    DWP14012 B mg

    DWP14012 B mg, tablet, once daily, oral administration for up to 4 weeks

    Drug: DWP14012 B mg

  • Placebo comparator
    Placebo

    Placebo, tablet, once daily, oral administration for up to 4 weeks

    Drug: Placebo

Interventions

  • The participants will receive treatment of DWP14012 A mg, tablet, orally, once daily and DWP14012 B mg placebo-matching tablet, orally, once daily for up to 4 weeks.

  • The participants will receive treatment of DWP14012 B mg, tablet, orally, once daily and DWP14012 A mg placebo-matching tablet, orally, once daily for up to 4 weeks.

  • DrugPlacebo

    The participants will receive treatment of DWP14012 A mg placebo-matching tablet, orally, once daily and DWP14012 B mg placebo-matching tablet, orally, once daily for up to 4 weeks.

06

What researchers measure

Primary outcomes

  1. 1. Percentage of patients with complete resolution of major symptoms (heartburn and acid regurgitation) at 4-week

    defined as no episodes of symptom during the last 7 days of treatment, using Reflux Disease Questionnaire(RDQ)

    Time frame: 4 week

Secondary outcomes

  1. Reflux disease symptom assessment using RDQ(Reflux disease questionnaire)

    Time frame: 2 week, 4 week

  2. Reflux disease symptom assessment using Subject diary

    Time frame: 4 week

  3. Quality of Life assessment using PAGI-QoL

    Time frame: 4 week

  4. Use of rescue medication

    Time frame: 4 week

07

Study locations

1 of 1 sites recruiting
  • Hanyang University Medical Center
    Seoul, Korea, Republic of
    Recruiting
    • Ohyoung Lee · Contactirb@hyumc.com · 82-2-2290-9652
    • Ohoyoung Lee · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2019 (actual). Primary completion is estimated for Feb 2020, 12 months after the start.

Of 21 phase 3 interventional studies under Gastroesophageal Reflux, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 49. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2019
First posted
Jan 22, 2019
StartActual
Feb 7, 2019
Primary completionEst.
Feb 2020
CompletionEst.
Feb 2020
Last update
Jun 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03811080
Responsible party
Sponsor
First posted
Jan 22, 2019
Start date
Feb 7, 2019
Primary completion
Feb 2020 (estimated)
Completion
Feb 2020 (estimated)
Last update
Jun 25, 2019

Study contacts

Daewoong Pharmaceutical Co. LTD.
Contact

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fexuprazan

Start the discussion